Literature DB >> 21567161

Assessment of neovascular permeability in a pancreatic tumor model using dynamic contrast-enhanced (DCE) MRI with contrast agents of different molecular weights.

Louke J Delrue1, Veerle Casneuf, Nancy Van Damme, Peter Blanckaert, Marc Peeters, Wim P Ceelen, Philippe C O Duyck.   

Abstract

OBJECT: We evaluated the relationship of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)-derived pharmacokinetic parameters and contrast agents with different molecular weights (MW) in a pancreatic tumor mouse model.
MATERIALS AND METHODS: Panc02 tumors were induced in mice at the hind leg. DCE-MRI was performed using Gadolinium (Gd)-based contrast agents with different MW: Gd-DOTA (0.5 kDa), P846 (3.5 kDa), and P792 (6.47 kDa). Quantitative vascular parameters (AUC, K(trans), V(e), and V(p)) were calculated according to a modified Tofts two-compartment model. Values for all contrast groups were compared for tumor and control (muscle) tissues.
RESULTS: Values for K(trans) and V(e) were significantly higher in tumor tissue than in muscle tissue. When comparing contrast agents, lowest absolute K(trans) values were observed using P792. The relative increase in K(trans) in tumor tissue compared with normal tissue was highest after the use of P792. In both tumor and normal tissues, K(trans) decreased with increasing molecular weight of the contrast agent used.
CONCLUSION: It was demonstrated that values for the different DCE-MRI vascular (permeability) parameters are highly dependent on the contrast agent used. Due to their potential to better differentiate tumor from muscle tissue, higher molecular weight contrast agents show promise when evaluating tumors using DCE-MRI.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21567161     DOI: 10.1007/s10334-011-0256-9

Source DB:  PubMed          Journal:  MAGMA        ISSN: 0968-5243            Impact factor:   2.310


  33 in total

1.  An exciting and challenging role for the advanced contrast MR imaging.

Authors:  W T Yuh
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

Review 2.  In vivo monitoring of tumor angiogenesis with MR imaging.

Authors:  R C Brasch; K C Li; J E Husband; M T Keogan; M Neeman; A R Padhani; D Shames; K Turetschek
Journal:  Acad Radiol       Date:  2000-10       Impact factor: 3.173

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

Review 4.  Functional MRI for anticancer therapy assessment.

Authors:  A R Padhani
Journal:  Eur J Cancer       Date:  2002-11       Impact factor: 9.162

5.  The evaluation of esophageal adenocarcinoma using dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Eugene Y Chang; Xin Li; Michael Jerosch-Herold; Ryan A Priest; C Kristian Enestvedt; Jingang Xu; Charles S Springer; Blair A Jobe
Journal:  J Gastrointest Surg       Date:  2007-09-01       Impact factor: 3.452

6.  New model for analysis of dynamic contrast-enhanced MRI data distinguishes metastatic from nonmetastatic transplanted rodent prostate tumors.

Authors:  Xiaobing Fan; Milica Medved; Jonathan N River; Marta Zamora; Claire Corot; Philippe Robert; Philippe Bourrinet; Martin Lipton; Rita M Culp; Gregory S Karczmar
Journal:  Magn Reson Med       Date:  2004-03       Impact factor: 4.668

7.  P846, a new gadolinium based low diffusion magnetic resonance contrast agent, in characterizing occlusive infarcts, reperfused ischemic myocardium and reperfused infarcts in rats.

Authors:  Alexis Jacquier; Matthew Bucknor; Loi Do; Philippe Robert; Claire Corot; Charles B Higgins; Maythem Saeed
Journal:  MAGMA       Date:  2008-04-30       Impact factor: 2.310

8.  Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology: Theory, Data Acquisition, Analysis, and Examples.

Authors:  Thomas E Yankeelov; John C Gore
Journal:  Curr Med Imaging Rev       Date:  2009-05-01

9.  P792: a rapid clearance blood pool agent for magnetic resonance imaging: preliminary results.

Authors:  M Port; C Corot; O Rousseaux; I Raynal; L Devoldere; J M Idée; A Dencausse; S Le Greneur; C Simonot; D Meyer
Journal:  MAGMA       Date:  2001-05       Impact factor: 2.533

10.  Recombinant human erythropoietin alpha modulates the effects of radiotherapy on colorectal cancer microvessels.

Authors:  W Ceelen; T Boterberg; P Smeets; N Van Damme; P Demetter; O Zwaenepoel; L Cesteleyn; P Houtmeyers; M Peeters; P Pattyn
Journal:  Br J Cancer       Date:  2007-02-13       Impact factor: 7.640

View more
  7 in total

1.  Differentiation between treatment-related changes and progressive disease in patients with high grade brain tumors using support vector machine classification based on DCE MRI.

Authors:  Moran Artzi; Gilad Liberman; Guy Nadav; Deborah T Blumenthal; Felix Bokstein; Orna Aizenstein; Dafna Ben Bashat
Journal:  J Neurooncol       Date:  2016-01-11       Impact factor: 4.130

Review 2.  The role of stroma in pancreatic cancer: diagnostic and therapeutic implications.

Authors:  Mert Erkan; Simone Hausmann; Christoph W Michalski; Alexander A Fingerle; Martin Dobritz; Jörg Kleeff; Helmut Friess
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-06-19       Impact factor: 46.802

3.  Detection of in vivo enzyme activity with CatalyCEST MRI.

Authors:  Byunghee Yoo; Vipul R Sheth; Christine M Howison; Matthew J K Douglas; Carlos T Pineda; Erin A Maine; Amanda F Baker; Mark D Pagel
Journal:  Magn Reson Med       Date:  2014-03       Impact factor: 4.668

4.  Dynamic Contrast-Enhanced MRI Using a Macromolecular MR Contrast Agent (P792): Evaluation of Antivascular Drug Effect in a Rabbit VX2 Liver Tumor Model.

Authors:  Hee Sun Park; Joon Koo Han; Jeong Min Lee; Young Il Kim; Sungmin Woo; Jung Hwan Yoon; Jin-Young Choi; Byung Ihn Choi
Journal:  Korean J Radiol       Date:  2015-08-21       Impact factor: 3.500

Review 5.  Contrast agents in dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Yuling Yan; Xilin Sun; Baozhong Shen
Journal:  Oncotarget       Date:  2017-06-27

6.  Preclinical evaluation of Gd-DTPA and gadomelitol as contrast agents in DCE-MRI of cervical carcinoma interstitial fluid pressure.

Authors:  Tord Hompland; Christine Ellingsen; Einar K Rofstad
Journal:  BMC Cancer       Date:  2012-11-22       Impact factor: 4.430

7.  Complementary role of computed tomography texture analysis for differentiation of pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumors in the portal-venous enhancement phase.

Authors:  Christian Philipp Reinert; Karolin Baumgartner; Tobias Hepp; Michael Bitzer; Marius Horger
Journal:  Abdom Radiol (NY)       Date:  2020-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.